Effectiveness, tolerability and safety of azithromycin 1% in DuraSite® for acute bacterial conjunctivitis

Patient Preference and Adherence

Volumn 4, Issue , 2010, Pages 69-76

  McLean, Susannah ^a   Sheikh, Aziz ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Azithromycin 1 in DuraSite ; Bacterial eye infection; Conjunctivitis

Indexed keywords

EID: 77954583035     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Dart J. Eye disease at a community health centre. BMJ. 1986;293: 1477-1480.
2. McDonnell P. How do general practitioners manage eye disease in the community? Br J Opthalmol. 1998;72:733-376.
3. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract. 2001;51:473-477.
4. Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2006;2:CD001211.
5. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. Br J Gen Pract. 2005;55:962-964.
6. Rose P, Harnden A, Brueggemann A, Perera, Sheikh A, Crook D, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomized double-blind placebo-controlled trial. Lancet. 2005;366:37-43.
7. West S. Azithromycin for control of trachoma. Community Eye Health. 1999;12:55-56.
8. Everitt H, Little P. How do GPs diagnose and manage acute infective conjunctivitis? A GP survey. Fam Pract. 1999;12:55-56.
9. Perry H, Donnenfeld D. Issues in the use of preservative-free topicals Manag Care. 2003;12 Suppl:39-42.
10. Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1(1):3-10.
11. Buznach N, Dagan R, Greenberg D. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J. 2005;24:823-828.
12. Friedlaender MH, Protzko E. Response to correspondence from Lichtenstein and Granet Re: Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitis. Clin Ophthalmol. 2008;2(1):242-244.
13. McCracken G. Microbiologic activity of the newer macrolide antibiotics. Pediatr Infect Dis J. 1997;16:432-437.
14. Ohnsman C, Ritterband D, O'Brien T, Girgis D, Kabat A. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Curr Med Res Opin. 2007;23:2241-2249.
15. Gigliotti F, Hendley J, Morgan J, Michaels R, Dickens M, Lohr J. Efficacy of topical antibiotic therapy in acute conjunctivitis in children. J Pediatr. 1984;104:623-626.
16. Leibowitz H. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112:295-33S.
17. Miller I, Wittreich H, Vogel R, Cook T. The safety and efficacy of topical norfloxacin compared with placebo in the treatment of acute bacterial conjunctivitis. Eur J Ophthlamol. 1992;258-266.
18. Rietveld R, Tiet Gd, Bindels P, Bink D, Sloos J, Weert HV. The treatment of acute infectious conjunctivitis with fusidic acid: a randomized controlled trial. Br J Gen Pract. 2005;559(924-930).
19. Everitt H, Little P, Smith P. A randomized controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ. 2006;333:321.
20. Leibovici L, Lievre M. Medicalization: peering from the inside. BMJ. 2002;324:866.
21. Sheikh A. Delayed prescribing of antibiotics is an effective strategy in managing acute conjunctivitis; J Pediatr. 2007;150:114-115.
22. Little P, Gould C, Williamson I, Warner G, Ganrley M, Kinmonth A. Reattendance and complications in a randomized trial of prescribing strategies for sore throat: the medicalizing effect of prescribing antibiotics. BMJ. 1997;314:177-182.
23. Abelson M, Heller W, Shapiero A, et al. clinical cure of bacterial conjunctivitis with azithromycin1%: vehicle-controlled double-masked clinical trial. Am J Ophthalmol. 2008;145: 959-965.
24. Abelson M, Heller W. Efficacy of azithromycin 1% eye drops vs vehicle as first line therapy for bacterial conjunctivitis. Unpublished study the Cochrane Register of Controlled Trials (CENTRAL). 2006;ID CN00634804.
25. Abelson M, Protzko E, Shapiero A, Garces-Soldana A, Bowman L. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis Clin Ophthalmol. 2007;1: 177-182.
26. Heller W, Abelson M, Group TAS. Safety and tolerabiltiy of azithromycin 1% eye drops as anti-infective therapy for bacteria conjunctivitis. Unpublished study for the Cochrane Register of Controlled Trials (CENTRAL). Study ID CN 00634521.
27. Protzko E, Bowman L, Abelson M, Shapiero A, Group TACS. Phase 3 safety comparisons for 1% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48(3425-3429).
28. Granet D, Lichtenstan SJ, Onofney B, Katz JA. An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in durasite. Clin Ophthalmol. 2007;1:133-139.
29. Bowman L, Si E, Pang J, Archibad R, Friedlaender M. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J Ocul Pharmacol Ther.2009;2:133-139.
30. Si PC, Bowman L, Hosseini K. Ocular pharmacokinetics of Azasite Xtra - 2% azithromycin formulated in a Durasite delivery system. Curr Eye Res. 2009;34:485-491.
31. Dorfman M, Wagner R, Jamison T, Bell B, Stroman DW. The pharmacodynamic properties of azithromycin in a kinetics of kill model and implications for bacterial conjunctivitis treatment. Adv Ther. 2008;25:208-217.
32. Lichtenstein S, Granet D. Fluoroquinolones compared to 1% azithromycin in durasite for bacterial conjunctivitis Clin Ophthalmol. 2007;1:519-525.
33. Winfield A, Jessiman D, Silliams A. A study of the causes of noncompliance by patients prescribed eyedrops. Br J Opthalmol. 1990;74: 477-480.
34. Jampel H, Schwartz G, Robin A. Patient preference for eye drop characteristics: a willingness to pay analysis. Arch Ophthalmol. 2003;121:540-546.
35. FDA. Patient information leaflet NDA 50-810. Revised 5/2007. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm?fuseactioncSearch. [Label Approval History] Accessed December 7, 2009.